The Corporate Reputation of Canadian Pharma, 2023-2024 – 100 Patient Groups Present their Views – Access to New Medicines Chief Among the Difficulties Experienced, due to Regulatory Delays – ResearchAndMarkets.com
DUBLIN — “The Corporate Reputation of Pharma in 2023/2024 – The Patient Perspective – Canada Edition – The Views of 100 Canadian Patient Groups” report has been added to ResearchAndMarkets.com’s offering. This review contains the results of a November 2023 to late-February 2024 survey, answered by 100 Canadian patient groups. The 100 respondent Canadian patient […] Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
